Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation

Summary

We tested the hypothesis that plasma fibrin clot structure/function is unfavourably altered in patients with antiphospholipid syndrome (APS). Ex vivo plasma clot permeability, turbidity and susceptibility to lysis were determined in 126 consecutive patients with APS enrolled five months or more since thrombotic event vs 105 controls. Patients with both primary and secondary APS were characterised by 11% lower clot permeability (p<0.001), 4.8% shorter lag phase (p<0.001), 10% longer clot lysis time (p<0.001), and 4.7% higher maximum level of D-dimer released from clots (p=0.02) as compared to the controls. Scanning electron microscopy images confirmed denser fibrin networks composed of thinner fibres in APS. Clots from patients with “triple-antibody positivity” were formed after shorter lag phase (p=0.019) and were lysed at a slower rate (p=0.004) than in the remainder. Clots from APS patients who experienced stroke and/or myocardial infarction were 8% less permeable (p=0.01) and susceptible to lysis (10.4% longer clot lysis time [p=0.006] and 4.5% slower release of D-dimer from clots [p=0.01]) compared with those following venous thromboembolism alone. Multivariate analysis adjusted for potential confounders showed that in APS patients, lupus anticoagulant and “triple-positivity” were the independent predictors of clot permeability, while “triple-positivity” predicted lysis time. We conclude that APS is associated with prothrombotic plasma fibrin clot phenotype, with more pronounced abnormalities in arterial thrombosis. Molecular background for this novel prothrombotic mechanism in APS remains to be established.

Keywords

Antiphospholipid syndrome - plasma fibrin clot structure - fibrinolysis

• References

• 1 Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368: 1033-1044.
• 2 Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376: 1498-1509.
• 3 Rodrigues CE, Carvalho JF, Shoenfeld Y. Neurological manifestations of antiphospholipid syndrome. Eur J Clin Invest 2010; 40: 350-359.
• 4 Arnson Y, Shoenfeld Y, Alon E. et al. The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum 2010; 40: 97-108.
• 5 Soltész P, Szekanecz Z, Kiss E. et al. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev 2007; 06: 379-386.
• 6 Marchetti T, Cohen M, Gris JC. et al. Diagnosis and management of obstetrical antiphospholipid syndrome: where do we stand?. Pol Arch Med Wewn 2013; 123: 713-720.
• 7 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 04: 295-306.
• 8 Musial J, Swadzba J, Motyl A. et al. Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis. J Rheumatol 2003; 30: 723-730.
• 9 Pengo V, Ruffatti A, Legnani C. et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118: 4714-4718.
• 10 Vega-Ostertag ME, Pierangeli SS. Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets. Curr Rheumatol Rep 2007; 09: 190-197.
• 11 Musiał J, Swadzba J, Jankowski M. et al. Thrombin generation measured ex vivo following microvascular injury is increased in SLE patients with antiphospholipid-protein antibodies. Thromb Haemost 1997; 78: 1173-1177.
• 12 Krone KA, Allen KL, McCrae KR. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep 2010; 12: 53-57.
• 13 Mackworth-Young CG. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 2004; 136: 393-401.
• 14 Undas A, Ariëns RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31: e88-99.
• 15 Undas A. Acquired dysfibrinogenemia in atherosclerotic vascular disease. Pol Arch Med Wewn 2011; 121: 110-119.
• 16 Undas A, Szuldrzynski K, Stepien E. et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2007; 196: 551-558.
• 17 Collet JP, Allali Y, Lesty C. et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573.
• 18 Undas A, Podolec P, Zawilska K. et al. Altered fibrin clot structure/function as a novel risk factor for cryptogenic ischaemic stroke. Stroke 2009; 40: 1499-1501.
• 19 Okraska-Bylica A, Wilkosz T, Słowik L. et al. Altered fibrin clot properties in patients with premature peripheral artery disease. Pol Arch Med Wewn 2012; 122: 608-615.
• 20 Undas A, Zawilska K, Ciesla-Dul M. et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114: 4272-4278.
• 21 Zolcinski M, Ciesla-Dul M, Undas A. Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism. Thromb Haemost 2012; 107: 1180-1182.
• 22 Sciascia S, Roccatello D, Bertero MT. et al. 8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study. Inflamm Res 2012; 61: 809-816.
• 23 Kwasny-Krochin B, Gluszko P, Undas A. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis. Thromb Res 2010; 126: 11-16.
• 24 Bertsias G, Carvera R, Boumpas TD. Systemic lupus erythematosus: pathogenesis and clinical features. Bijlsma JWJ. EULAR Textbook of Rheumatic Diseases. 2012. 1st. London BMJ Group; 476-505.
• 25 Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med 2011; 270: 110-122.
• 26 Pengo V, Tripodi A, Reber G. et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 07: 1737-1740.
• 27 Mills JD, Ariens RA, Mansfield MW. et al. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-1942.
• 28 Blombäck B, Carlsson K, Hessel B. et al. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
• 29 Pankiw-Bembenek O, Zalewski J, Goralczyk T. et al. A history of early stent thrombosis is associated with prolonged clot lysis time. Thromb Haemost 2012; 107: 513-520.
• 30 de la Red G, Tassies D, Espinosa G. et al. Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels. Thromb Haemost 2009; 101: 312-316.
• 31 Gajos G, Zalewski J, Rostoff P. et al. Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). Arterioscler Thromb Vasc Biol 2011; 31: 1696-1702.
• 32 Boehm TK, DeNardin E. Fibrinogen binds IgG antibody and enhances IgG-mediated phagocytosis. Hum Antibodies 2008; 17: 45-56.
• 33 Talens S, Leebeek FWG, Demmers JAA. et al. Identification of fibrin clot-bound plasma proteins. PLoS ONE 2012; 07: e41966.
• 34 Undas A, Celinska-Löwenhoff M, Löwenhoff T. et al. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 04: 1029-1036.
• 35 Yasuda S, Atsumi T, Ieko M. et al. Nicked beta2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 2004; 103: 3766-3772.
• 36 Bu C, Gao L, Xie W. et al. Beta2-glycoprotein I is a cofactor for tissue plasminogen activator-mediated plasminogen activation. Arthritis Rheum 2009; 60: 559-568.
• 37 Ieko M, Yoshida M, Naito S. et al. Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation. Int J Hematol 2010; 91: 776-783.
• 38 Yang CD, Hwang KK, Yan W. et al. Identification of antiplasmin antiobodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004; 172: 5765-5773.
• 39 Chen PP, Yang CD, Ede K. et al. Some antiphospholipid antibodies bind to hemostasis and fibrinolysis proteases and promote thrombosis. Lupus 2008; 17: 916-921.
• 40 Cugno M, Cabibbe M, Galli M. et al. Antibodies to tissue-type plasminogen activator (t-PA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of t-PA in 2 patients. Blood 2004; 103: 2121-2126.
• 41 Meltzer ME, Lisman T, de Groot PhG. et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116: 113-121.
• 42 Fatah K, Silveira A, Tornval P. et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-540.
• 43 Ajjan RA, Standeven KF, Khanbhai M. et al. Effects of aspirin on clot structure and fibrinolysis using a novel cellular system. Arterioscler Thromb Vasc Biol 2009; 29: 712-717.
• 44 Standeven KF, Uitte de Willige S, Carter AM. et al. Heritability of clot formation. Semin Thromb Haemost 2009; 35: 458-467.